UK Psychedelics: Compass Pathways and Awakn Life Sciences Hit New Milestones
The UK Medicines and Healthcare Regulatory Agency (MHRA) has given the green light to two separate Phase 3 trials conducted by Compass Pathways and Awakn Life Sciences. The trials will focus on Treatment-Resistant Depression and Severe Alcohol Use Disorder (SAUD), respectively.
Compass Pathways plc will launch the UK arm of its Phase 3 program on psilocybin therapy COMP360 for Treatment-Resistant Depression (TRD). This program is reportedly the largest of its kind and will take place at the newly-opened Centre for Mental Health Research and Innovation in London. Developed in partnership with South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London, the new research and innovation center will be run by experts in the field. Compass CEO Kabir Nath emphasized the significance of these initiatives in addressing urgent mental health needs.
Awakn Life Sciences has also received clinical trial authorization from the MHRA and ethical approval from the Health Research Authority in the UK for a Phase 3 trial on their lead program AWKN-P001 for the treatment of Severe Alcohol Use Disorder (SAUD). The company’s CEO, Anthony Tennyson, views this as a pivotal step in their journey and looks forward to delivering a potentially transformative therapy to the market.
The approval of these trials represents a significant milestone in the psychedelic research and treatment landscape in the UK.
